Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 2/2017

01-06-2017 | Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Management of Rare Breast Tumors and Male Breast Cancer

Author: David M. Euhus

Published in: Current Breast Cancer Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

There is very little clinical trial data available to guide the management of uncommon breast cancers. This review draws on classic and recent retrospective data to synthesize a clearer understanding of the biology and behavior of these rare tumors.

Recent Findings

Avoid disfiguring surgery in the pursuit of very wide margins for benign phyllodes tumors unless there are adverse histological features. Encapsulated papillary carcinoma is very good prognosis breast cancer; do not over treat. Metaplastic carcinoma is a basal type breast cancer that may be more responsive to “BRCA1-like” treatments. Complete excision of the capsule is curative for most implant-associated anaplastic large cell lymphomas. Aromatase inhibitors are still controversial for male breast cancer; tamoxifen is standard.

Summary

Available data are useful for guiding the treatment of rare breast cancers, but it must be recognized that there is still a great deal to be learned about each of these entities.
Literature
1.
DeLair DF, Corben AD, Catalano JP, Vallejo CE, Brogi E, Tan LK. Non-mammary metastases to the breast and axilla: a study of 85 cases. Mod Pathol. 2013;26(3):343–9.CrossRefPubMed
2.
Adesoye T, Neuman HB, Wilke LG, Schumacher JR, Steiman J, Greenberg CC. Current trends in the management of phyllodes tumors of the breast. Ann Surg Oncol. 2016;23(10):3199–205.CrossRefPubMedPubMedCentral
3.
•• Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, et al. Phyllodes tumours of the breast: a consensus review. Histopathology. 2016;68(1):5–21. A very thorough and thoughtful review of phyllodes tumors CrossRefPubMedPubMedCentral
4.
Cani AK, Hovelson DH, McDaniel AS, Sadis S, Haller MJ, Yadati V, et al. Next-gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors. Mol Cancer Res. 2015;13(4):613–9.CrossRefPubMedPubMedCentral
5.
Cancer IAfRo. WHO classification of tumours of the breast. 4th ed. Geneva: World Health Organization; 2012.
6.
Network NCC. Breast cancer. Fort Washington (PA): NCCN Clinical Practice Guidelines in Oncology v.2.2016; 2016.
7.
Tan PH, Thike AA, Tan WJ, Thu MM, Busmanis I, Li H, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol. 2012;65(1):69–76.CrossRefPubMed
8.
Cowan ML, Argani P, Cimino-Mathews A. Benign and low-grade fibroepithelial neoplasms of the breast have low recurrence rate after positive surgical margins. Mod Pathol. 2016;29(3):259–65.CrossRefPubMed
9.
Moutte A, Chopin N, Faure C, Beurrier F, Ho Quoc C, Guinaudeau F, et al. Surgical management of benign and borderline phyllodes tumors of the breast. Breast J. 2016;22(5):547–52.CrossRefPubMed
10.
Shaaban M, Barthelmes L. Benign phyllodes tumours of the breast: (Over) treatment of margins - A literature review. Eur J Surg Oncol. 2016.
11.
Kim S, Kim JY. Analysis of phyllodes tumor recurrence according to the histologic grade. Breast Cancer Res Treat. 2013;141(3):353–63.CrossRefPubMed
12.
• Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 2007;14(10):2961–70. A phyllodes series with very long follow-up and systematic analysis of factor prediciting local recurrence risk CrossRefPubMed
13.
Cheng SP, Chang YC, Liu TP, Lee JJ, Tzen CY, Liu CL. Phyllodes tumor of the breast: the challenge persists. World J Surg. 2006;30(8):1414–21.CrossRefPubMed
14.
Borhani-Khomani K, Talman ML, Kroman N, Tvedskov TF. Risk of local recurrence of benign and borderline phyllodes tumors: a Danish population-based retrospective study. Ann Surg Oncol. 2016;23(5):1543–8.CrossRefPubMed
15.
• Yom CK, Han W, Kim SW, Park SY, Park IA, Noh DY. Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast. Ann Surg Oncol. 2015;22(9):2912–8. A recent series that proposes a strategy for recognizing phyllodes tumors with high risk of recurrence CrossRefPubMed
16.
Mitus JW, Blecharz P, Walasek T, Reinfuss M, Jakubowicz J, Kulpa J. Treatment of patients with distant metastases from phyllodes tumor of the breast. World J Surg. 2016;40(2):323–8.CrossRefPubMed
17.
•• Barth Jr RJ, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009;16(8):2288–94. A prospective study demonstrating the value of adjuvant radiation therapy in borderline and malignant phyllodes CrossRefPubMedPubMedCentral
18.
Belkacemi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magne N, Malard Y, et al. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys. 2008;70(2):492–500.CrossRefPubMed
19.
Rakha EA, Gandhi N, Climent F, van Deurzen CH, Haider SA, Dunk L, et al. Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. Am J Surg Pathol. 2011;35(8):1093–103.CrossRefPubMed
20.
Esposito NN, Dabbs DJ, Bhargava R. Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases. Am J Clin Pathol. 2009;131(2):228–42.CrossRefPubMed
21.
• Grabowski J, Salzstein SL, Sadler GR, Blair S. Intracystic papillary carcinoma: a review of 917 cases. Cancer. 2008;113(5):916–20. The largest series of encapsulated papillary carcinoma with long-term outcome data CrossRefPubMedPubMedCentral
22.
Weigelt B, Eberle C, Cowell CF, Ng CK, Reis-Filho JS. Metaplastic breast carcinoma: more than a special type. Nat Rev Cancer. 2014;14(3):147–8.CrossRefPubMed
23.
Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69(10):4116–24.CrossRefPubMedPubMedCentral
24.
Dieci MV, Smutna V, Scott V, Yin G, Xu R, Vielh P, et al. Whole exome sequencing of rare aggressive breast cancer histologies. Breast Cancer Res Treat. 2016;156(1):21–32.CrossRefPubMed
25.
Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26(14):2126–32.CrossRefPubMed
26.
Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1):166–73.CrossRefPubMed
27.
Nelson RA, Guye ML, Luu T, Lai LL. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann Surg Oncol. 2015;22(1):24–31.CrossRefPubMed
28.
Aydiner A, Sen F, Tambas M, Ciftci R, Eralp Y, Saip P, et al. Metaplastic breast carcinoma versus triple-negative breast cancer: survival and response to treatment. Medicine (Baltimore). 2015;94(52):e2341.CrossRef
29.
Rakha EA, Tan PH, Varga Z, Tse GM, Shaaban AM, Climent F, et al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Br J Cancer. 2015;112(2):283–9.CrossRefPubMed
30.
• Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, et al. Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011;29(19):e572–5. The only prospective treatment trial focusing on metaplastic carcinoma CrossRefPubMed
31.
Mehta RS, Schubbert T, Marshall J, Carpenter PM. Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli. Clin Breast Cancer. 2009;9(1):56–9.CrossRefPubMed
32.
Takuwa H, Ueno T, Ishiguro H, Mikami Y, Kanao S, Takada M, et al. A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy. Breast Cancer. 2014;21(4):504–7.CrossRefPubMed
33.
Keech Jr JA, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg. 1997;100(2):554–5.CrossRefPubMed
34.
de Jong D, Vasmel WL, de Boer JP, Verhave G, Barbe E, Casparie MK, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA. 2008;300(17):2030–5.CrossRefPubMed
35.
•• Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34(2):160–8. The largest reported series of implant-associated anaplastic large cell lymphoma with outcome by stage and treatment, and recommendations for a new staging scheme CrossRefPubMed
36.
Bogina G, Munari E, Brunelli M, Bortesi L, Marconi M, Sommaggio M, et al. Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. Histopathology. 2016;68(3):422–32.CrossRefPubMed
37.
• Inno A, Bogina G, Turazza M, Bortesi L, Duranti S, Massocco A, et al. Neuroendocrine carcinoma of the breast: current evidence and future perspectives. Oncologist. 2016;21(1):28–32. A thorough recent review of neuroendocrine carcinoma of the breast CrossRefPubMed
38.
Kanat O, Kilickap S, Korkmaz T, Ustaalioglu Oven BB, Canhoroz M, Cubukcu E, et al. Primary small cell carcinoma of the breast: report of seven cases and review of the literature. Tumori. 2011;97(4):473–8.PubMed
39.
Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014;14:147.CrossRefPubMedPubMedCentral
40.
Cloyd JM, Yang RL, Allison KH, Norton JA, Hernandez-Boussard T, Wapnir IL. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Res Treat. 2014;148(3):637–44.CrossRefPubMed
41.
Lae M, Lebel A, Hamel-Viard F, Asselain B, Trassard M, Sastre X, et al. Can c-myc amplification reliably discriminate postradiation from primary angiosarcoma of the breast? Cancer Radiother. 2015;19(3):168–74.CrossRefPubMed
42.
Scow JS, Reynolds CA, Degnim AC, Petersen IA, Jakub JW, Boughey JC. Primary and secondary angiosarcoma of the breast: the Mayo Clinic experience. J Surg Oncol. 2010;101(5):401–7.PubMed
43.
Pandey M, Sutton GR, Giri S, Martin MG. Grade and prognosis in localized primary angiosarcoma. Clin Breast Cancer. 2015;15(4):266–9.CrossRefPubMed
44.
Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer. 2001;92(1):172–80.CrossRefPubMed
45.
Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren A. Soft tissue sarcoma after treatment for breast cancer—a Swedish population-based study. Eur J Cancer. 1998;34(13):2068–75.CrossRefPubMed
46.
Kadouri L, Sagi M, Goldberg Y, Lerer I, Hamburger T, Peretz T. Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations. Breast Cancer Res Treat. 2013;140(1):207–11.CrossRefPubMed
47.
Tidwell WJ, Haq J, Kozlowski KF, Googe PB. C-MYC positive angiosarcoma of skin and breast following MammoSite (R) treatment. Dermatol Online J. 2015;21(10).
48.
Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer. 1948;1(1):64–81.CrossRefPubMed
49.
Felmerer G, Dowlatshahi AS, Stark GB, Foldi E, Foldi M, Ahls MG, et al. Lymphangiosarcoma: is Stewart-Treves syndrome a preventable condition? Lymphat Res Biol. 2016;14(1):35–9.CrossRefPubMed
50.
• Depla AL, Scharloo-Karels CH, de Jong MA, Oldenborg S, Kolff MW, Oei SB, et al. Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review. Eur J Cancer. 2014;50(10):1779–88. A recent systematic review of secondary angiosarcoma of the breast CrossRefPubMed
51.
Smith TL, Morris CG, Mendenhall NP. Angiosarcoma after breast-conserving therapy: long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART). Acta Oncol. 2014;53(2):235–41.CrossRefPubMed
52.
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.CrossRefPubMed
53.
Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26(32):5269–74.CrossRefPubMed
54.
Gambini D, Visintin R, Locatelli E, Bareggi C, Galassi B, Runza L, et al. Secondary breast angiosarcoma and paclitaxel-dependent prolonged disease control: report of two cases and review of the literature. Tumori. 2015;101(2):e60–3.PubMed
55.
Raina V, Sengar M, Shukla NK, Deo SS, Mohanty BK, Sharma D, et al. Complete response from thalidomide in angiosarcoma after treatment of breast cancer. J Clin Oncol. 2007;25(7):900–1.CrossRefPubMed
56.
Chen BJ, Wu YL, Tanaka Y, Zhang W. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci. 2014;10(10):1084–96.CrossRefPubMedPubMedCentral
57.
58.
Anderson WF, Althuis MD, Brinton LA, Devesa S. Is male breast cancer similar or different from female breast cancer? Br Cancer Res Treat. 2004;83:77–86.CrossRef
59.
60.
•• Brinton LA, Cook MB, McCormack V, Johnson KC, Olsson H, Casagrande JT, et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst. 2014;106(3):djt465. One of the largests recent studies examining risk factors for male breast cancer CrossRefPubMedPubMedCentral
61.
Brinton LA, Key TJ, Kolonel LN, Michels KB, Sesso HD, Ursin G, et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol. 2015;33(18):2041–50.CrossRefPubMedPubMedCentral
62.
63.
Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, et al. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol. 2012;25(3):398–404.CrossRefPubMed
64.
Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne D, et al. Mutational profiling of familial male breast cancers reveals similarities with luminal a female breast cancer with rare TP53 mutations. Br J Cancer. 2014;111(12):2351–60.CrossRefPubMedPubMedCentral
65.
•• Yu XF, Yang HJ, Yu Y, Zou DH, Miao LL. A prognostic analysis of male breast cancer (MBC) compared with post-menopausal female breast cancer (FBC). PLoS One. 2015;10(8):e0136670. This study convincingly shows that prognoisis for male breast cancer is worse than postmenopausal female breast cancer CrossRefPubMedPubMedCentral
66.
Boughey JC, Bedrosian I, Meric-Bernstam F, Ross MI, Kuerer HM, Akins JS, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006;203(4):475–80.CrossRefPubMed
67.
Flynn LW, Park J, Patil SM, Cody 3rd HS, Port ER. Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. J Am Coll Surg. 2008;206(4):616–21.CrossRefPubMed
68.
Grenader T, Yerushalmi R, Tokar M, Fried G, Kaufman B, Peretz T, et al. The 21-gene recurrence score assay (Oncotype DX) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort. Oncology. 2014;87(1):1–6.CrossRefPubMed
69.
Maugeri-Sacca M, Barba M, Vici P, Pizzuti L, Sergi D, De Maria R, et al. Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. Breast Cancer Res Treat. 2014;147(2):227–35.CrossRefPubMed
70.
• Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Rohl FW, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013;137(2):465–70. Found that in the adjuvant setting, tamoxifen is superior to aromatase inhibitors for male breast cancer CrossRefPubMed
71.
Zagouri F, Sergentanis TN, Azim Jr HA, Chrysikos D, Dimopoulos MA, Psaltopoulou T. Aromatase inhibitors in male breast cancer: a pooled analysis. Breast Cancer Res Treat. 2015;151(1):141–7.CrossRefPubMed
72.
Foerster R, Foerster FG, Wulff V, Schubotz B, Baaske D, Wolfgarten M, et al. Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer. 2011;11:335.CrossRefPubMedPubMedCentral
73.
Marchal F, Salou M, Marchal C, Lesur A, Desandes E. Men with breast cancer have same disease-specific and event-free survival as women. Ann Surg Oncol. 2009;16(4):972–8.CrossRefPubMed
74.
Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Laronningen S, et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol. 2011;29(33):4381–6.CrossRefPubMed
75.
Nilsson C, Holmqvist M, Bergkvist L, Hedenfalk I, Lambe M, Fjallskog ML. Similarities and differences in the characteristics and primary treatment of breast cancer in men and women—a population based study (Sweden). Acta Oncol. 2011;50(7):1083–8.CrossRefPubMed
76.
Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst. 2002;94(17):1330–2.CrossRefPubMed
77.
Hemminki K, Scelo G, Boffetta P, Mellemkjaer L, Tracey E, Andersen A, et al. Second primary malignancies in patients with male breast cancer. Br J Cancer. 2005;92(7):1288–92.CrossRefPubMedPubMedCentral
Metadata
Title
Management of Rare Breast Tumors and Male Breast Cancer
Author
David M. Euhus
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 2/2017
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-017-0243-x

Other articles of this Issue 2/2017

Current Breast Cancer Reports 2/2017 Go to the issue

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

New Guidelines on the Adequacy of Lumpectomy Margin Width in Patients with Ductal Carcinoma In Situ

Psycho-Oncology and Supportive Care (E Shinn and C Fagundes, Section Editors)

Caregiving Stress and Its Toll on Health From a Psychoneuroimmunological Perspective

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

New Approaches for Tailoring the Use of Radiotherapy in Early-Stage Breast Cancer

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

New Insights on the Role of Surgery for the Breast Primary Tumor in Patients Presenting With Stage IV Disease

Invited Commentary

Targeting HER2/3 in Breast Cancer

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Current Trends in Localization Techniques for Non-palpable Breast Lesions: Making the Invisible Visible
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits